• LAST PRICE
    3.7400
  • TODAY'S CHANGE (%)
    Trending Up0.0300 (0.8086%)
  • Bid / Lots
    3.6000/ 1
  • Ask / Lots
    3.8700/ 4
  • Open / Previous Close
    3.7300 / 3.7100
  • Day Range
    Low 3.5200
    High 3.8700
  • 52 Week Range
    Low 1.0400
    High 5.2400
  • Volume
    547,290
    average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Wednesday's close: 3.71
TimeVolumeTARA
09:32 ET141163.73
09:34 ET204793.715
09:36 ET151853.6445
09:38 ET54363.64
09:39 ET8503.612
09:41 ET18833.6268
09:43 ET24653.565
09:45 ET24513.57
09:48 ET18613.6699
09:50 ET5543.59
09:52 ET15003.67
09:54 ET1003.7
09:56 ET1003.65
09:57 ET19743.69
09:59 ET1003.655
10:06 ET10003.73
10:08 ET1003.7
10:10 ET14943.7599
10:12 ET90723.7922
10:14 ET15033.83
10:15 ET34503.7867
10:17 ET3003.795
10:21 ET1003.76
10:24 ET2003.76
10:26 ET1003.735
10:28 ET12153.715
10:32 ET5023.73
10:33 ET1003.76
10:39 ET16163.78
10:42 ET2003.76
10:46 ET5663.72
10:48 ET5503.72
10:50 ET3193.69
10:53 ET5403.72
11:02 ET6003.72
11:04 ET2183.69
11:08 ET7983.735
11:11 ET2003.725
11:18 ET42713.77
11:20 ET10003.79
11:22 ET12003.75
11:24 ET25743.785
11:26 ET164003.755
11:27 ET272873.74
11:29 ET48603.74
11:31 ET20503.74
11:33 ET6003.74
11:40 ET4003.755
11:42 ET24003.7487
11:47 ET43783.77
11:49 ET18003.77
11:51 ET148003.78
11:54 ET33943.8
11:56 ET285123.79
11:58 ET5143.8
12:00 ET7813.805
12:02 ET4283.8
12:03 ET1003.8
12:05 ET11973.765
12:07 ET11003.7899
12:09 ET170003.77
12:12 ET19003.78
12:14 ET45643.77
12:16 ET184913.79
12:18 ET16653.77
12:20 ET12923.74
12:23 ET4183.74
12:32 ET6453.7132
12:34 ET19473.7499
12:36 ET2003.735
12:38 ET1003.735
12:45 ET1003.75
12:48 ET9333.76
12:50 ET14663.79
12:56 ET3003.7823
12:57 ET3003.79
12:59 ET7373.78
01:15 ET11803.805
01:17 ET1003.82
01:19 ET1003.8
01:28 ET6013.765
01:33 ET13003.765
01:42 ET9873.7589
01:46 ET5003.76
01:48 ET5003.78
01:53 ET4003.79
01:55 ET1003.8
01:57 ET19343.81
02:02 ET19003.82
02:04 ET3003.82
02:08 ET2943.83
02:09 ET36003.82
02:11 ET12003.82
02:13 ET3653.84
02:15 ET32503.82
02:18 ET271923.71
02:20 ET37863.7
02:24 ET62163.7
02:29 ET11043.7
02:33 ET24953.6552
02:36 ET4003.69
02:40 ET3503.6688
02:42 ET87823.7199
02:44 ET226733.69
02:45 ET189243.7
02:47 ET185703.69
02:49 ET104003.71
02:51 ET16253.7
02:54 ET3003.7
02:56 ET11913.68
02:58 ET50003.7
03:00 ET94953.65
03:02 ET33503.65
03:03 ET12133.645
03:05 ET90773.66
03:07 ET29883.67
03:09 ET56403.65
03:14 ET2003.66
03:16 ET4003.66
03:18 ET1003.665
03:20 ET1003.68
03:21 ET7003.65
03:32 ET13883.655
03:34 ET6003.67
03:36 ET1003.67
03:38 ET12703.7
03:39 ET1003.695
03:41 ET17003.695
03:43 ET3303.7
03:45 ET18233.72
03:48 ET13003.72
03:50 ET22293.7199
03:52 ET7353.7009
03:54 ET3003.7
03:56 ET29373.74
03:57 ET10303.7014
03:59 ET277643.74
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesTARA
Protara Therapeutics Inc
76.4M
-1.0x
---
United StatesCVM
CEL-SCI Corp
77.7M
-2.1x
---
United StatesTPST
Tempest Therapeutics Inc
75.1M
-1.8x
---
United StatesVTVT
vTv Therapeutics Inc
77.9M
-3.2x
---
United StatesCGTX
Cognition Therapeutics Inc
78.1M
-2.1x
---
United StatesTIL
Instil Bio Inc
78.7M
-0.5x
---
As of 2024-05-16

Company Information

Protara Therapeutics, Inc. is a clinical-stage biotechnology company, which is engaged in advancing transformative therapies for people with cancer and rare diseases. The Company’s portfolio includes its lead candidate, TARA-002, an investigational cell-based therapy in development for the treatment of non-muscle invasive bladder cancer (NMIBC) and lymphatic malformations (LMs). The Company is evaluating TARA-002 in an ongoing Phase II trial in NMIBC patients with carcinoma in situ (CIS) who are unresponsive or naive to treatment with Bacillus Calmette-Guerin (BCG), as well as a Phase II trial in pediatric patients with LMs. In addition, the Company is developing IV Choline Chloride, an investigational phospholipid substrate replacement for patients on parenteral nutrition who are otherwise unable to meet their choline needs via oral or enteral routes.

Contact Information

Headquarters
345 Park Avenue South, 3Rd FloorNEW YORK, NY, United States 10010
Phone
646-844-0337
Fax
302-655-5049

Executives

Independent Chairman of the Board
Luke Beshar
President, Chief Executive Officer, Director
Jesse Shefferman
Chief Financial Officer
Patrick Fabbio
Chief Scientific Operations Officer
Jacqueline Zummo
Controller
Hannah Fry

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$76.4M
Revenue (TTM)
$0.00
Shares Outstanding
20.6M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
1.91
EPS
$-3.74
Book Value
$6.01
P/E Ratio
-1.0x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.